---
title: "Editas Medicine, Inc. (EDIT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/EDIT.US.md"
symbol: "EDIT.US"
name: "Editas Medicine, Inc."
industry: "Biotechnology"
datetime: "2026-06-14T03:00:29.611Z"
locales:
  - [en](https://longbridge.com/en/quote/EDIT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/EDIT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/EDIT.US.md)
---

# Editas Medicine, Inc. (EDIT.US)

## Company Overview

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.editasmedicine.com](https://www.editasmedicine.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-13T04:30:12.000Z

**Overall: D (0.71)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 238 / 390 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 7.97% |  |
| Net Profit YoY | 56.63% |  |
| P/B Ratio | 87.04 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 383654595.00 |  |
| Revenue | 38693000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -326.07% | E |
| Profit Margin | -281.59% | E |
| Gross Margin | -521.69% | E |
| Revenue YoY | 7.97% | C |
| Net Profit YoY | 56.63% | B |
| Total Assets YoY | -43.36% | E |
| Net Assets YoY | -92.94% | E |
| Cash Flow Margin | 128.96% | B |
| OCF YoY | 7.97% | C |
| Turnover | 0.19 | D |
| Gearing Ratio | 97.05% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Editas Medicine, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "7.97%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "56.63%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "87.04",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "383654595.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "38693000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-326.07%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-281.59%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-521.69%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "7.97%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "56.63%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-43.36%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-92.94%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "128.96%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "7.97%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.19",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "97.05%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.52 | 331/390 | - | - | - |
| PB | 87.04 | 448/390 | 17.71 | 14.10 | 8.82 |
| PS (TTM) | 9.92 | 162/390 | 7.51 | 6.00 | 4.63 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | CapForce Inc. (CFOR.US) | A | A | A | A | B | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-27T04:00:00.000Z

Total Analysts: **13**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 54% |
| Hold | 4 | 31% |
| Underweight | 2 | 15% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.50 |
| Highest Target | 15.00 |
| Lowest Target | 1.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/EDIT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/EDIT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/EDIT.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/EDIT.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**